

CLAIMS

1. An anti-P-selectin antibody or binding fragment thereof, for use in the treatment or prevention of a P-selectin mediated disorder and/or symptoms, wherein the antibody or binding fragment thereof is first provided in a loading phase, during which the subject receives a first amount of the antibody or binding fragment thereof over a given period of time, and then a further amount of the antibody or binding fragment thereof provided in a maintenance phase, during which the subject receives a lower amount of the antibody or binding fragment thereof over a given period of time.
2. An anti-P-selectin antibody or binding fragment thereof, for use according to claim 1, wherein anti-P-selectin antibody or binding fragment thereof comprises a heavy chain variable region comprising three CDRs comprising or consisting of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively and a light chain variable region comprising three CDRs comprising or consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, respectively.
3. An anti-P-selectin antibody or binding fragment thereof, for use according to claim 1 or 2, wherein the anti-P-selectin antibody or binding fragment thereof comprises a light chain variable region comprising or consisting of the sequence SEQ ID NO: 5 and a heavy chain variable region comprising or consisting of the sequence SEQ ID NO: 9.
4. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 3, wherein the antibody or binding fragment thereof is crizanlizumab or a binding fragment thereof.
5. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 4, wherein the P-selectin-mediated disorder and/or symptoms is sickle cell pain crisis.
6. An anti-P-selectin antibody or binding fragment thereof, for use in the prevention of sickle cell pain crisis according to claim 5.
7. An anti-P-selectin antibody or binding fragment thereof, for use in the reduction of annual rate of sickle cell pain crises according to claim 5 or 6.
8. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 5 to 7, wherein the antibody or binding fragment thereof is provided to a subject at an amount of between 1 mg/kg to 20 mg/kg in one or more loading doses followed by a plurality of maintenance doses, wherein average time intervals between the maintenance doses are longer than average time intervals following the one or more loading doses, or wherein the concentration of the loading doses is higher than the concentration of the maintenance doses.
9. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 8, wherein the anti-P-selectin antibody or binding fragment thereof is provided to the subject by an intravenous route.

10. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 9, wherein the antibody or binding fragment thereof is provided to the subject in a loading dose of between 2.5 mg/kg to 7.5 mg/kg, or preferably 2.5 mg/kg to 5 mg/kg.
11. An anti-P-selectin antibody or binding fragment thereof, for use according to claim 10, wherein the loading dose is 5 mg/kg or 7.5 mg/kg.
12. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 11, wherein the antibody or binding fragment thereof is provided to the subject in a maintenance dose of between 2.5 mg/kg to 7.5 mg/kg, or preferably 2.5 mg/kg to 5 mg/kg.
13. An anti-P-selectin antibody or binding fragment thereof, for use according to claim 12, wherein the maintenance dose is 5 mg/kg or 7.5 mg/kg.
14. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 13, wherein said loading dose and maintenance dose are equal, wherein time intervals between the maintenance doses are longer than time intervals between the loading doses.
15. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 13, wherein said loading dose is higher than said maintenance dose, wherein time intervals between the maintenance doses are equal with the time intervals between the loading doses.
16. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 15, wherein the antibody or binding fragment thereof is provided to the subject in two loading doses.
17. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 16, wherein the time interval between the loading doses is 2 weeks (+/- 3 days).
18. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1 to 17, wherein the time interval between the maintenance doses is 4 weeks (+/- 3 days).
19. Crizanlizumab or a binding fragment thereof for use in the prevention of a sickle cell pain crisis, wherein the antibody is first provided in a loading phase, during which the subject receives two loading doses of the antibody at an amount of between 2.5 mg/kg to 5 mg/kg and wherein the time interval between the two loading doses is 2 weeks (+/- 3 days), and then further provided in a maintenance phase, during which the subject receives a plurality of maintenance doses of the antibody at an amount of between 2.5 mg/kg to 5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks (+/- 3 days).
20. Crizanlizumab or a binding fragment thereof for use in the prevention of a sickle cell pain crisis according to claim 19, wherein the antibody is first provided in a loading phase,

during which the subject receives two loading doses of the antibody at an amount of 5 mg/kg and wherein the time interval between the two loading doses is 2 weeks (+/-3 days), and then further provided in a maintenance phase, during which the subject receives a plurality of maintenance doses of the antibody at an amount of 5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks (+/-3 days).

21. Crizanlizumab or a binding fragment thereof for use in the prevention of a sickle cell pain crisis according to claim 19, wherein the antibody is first provided in a loading phase, during which the subject receives two loading doses of the antibody at an amount of 7.5 mg/kg and wherein the time interval between the two loading doses is 2 weeks (+/-3 days), and then further provided in a maintenance phase, during which the subject receives a plurality of maintenance doses of the antibody at an amount of 7.5 mg/kg and wherein the time interval between the plurality of maintenance doses is 4 weeks (+/-3 days).
22. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 1-21 further in combination with hydroxyurea.
23. An anti-P-selectin antibody or binding fragment thereof, for use according to any one of the claims 19 to 22, wherein the anti-P-selectin antibody or binding fragment thereof is provided to the subject by an intravenous route.